

1 **Dynamics of the SARS-CoV-2 epidemic in the earliest-affected areas in Italy:**  
2 **Mass screening for SARS-CoV-2 serological positivity (SARS-2-SCREEN).**

3 Gabriele Pagani<sup>1</sup>, Dario Bernacchia<sup>1</sup>, Federico Conti<sup>1</sup>, Andrea Giacomelli<sup>1</sup>, Rossana  
4 Rondanin<sup>6</sup>, Vittore Sclaris, Patrizia Boracchi<sup>4</sup>, Cecilia Eugenia Gandolfi<sup>2</sup> Silvana Castaldi<sup>2,3</sup>,  
5 Elia Biganzoli<sup>4\*</sup>, Massimo Galli<sup>1\*</sup>.

6  
7 *1: Department of Clinical and Biomedical Sciences (DIBIC) "L. Sacco", University of Milan, Italy*

8 *2: Post graduate School in Public Health Dept Biomedical Sciences for Health, University of Milan, Italy*

9 *3: Fondazione IRCCS Ca' Granda Ospedale Maggiore policlinico di Milano, Italy*

10 *4: Department of Clinical Sciences and Community Health & DSRC, University of Milan, Italy.*

11 *5: Institut Curie-PSL Research University, CNRS, Sorbonne Université, UMR3664, F-75005, Paris, France.*

12 *6: Medispa s.r.l.*

13

14 \*Equally contributing Authors

15

16

17

18

19

20 **Corresponding Authors:**

21 Gabriele Pagani

22 [gabriele.pagani@unimi.it](mailto:gabriele.pagani@unimi.it)

23 ASST FBF-Sacco, Infectious Diseases Dep., III Division

24 Luigi Sacco Hospital

25 Via G.B. Grassi 74, 20157

26 Milan, Italy

27

28 Cecilia Eugenia Gandolfi

29 [cecilia.gandolfi@unimi.it](mailto:cecilia.gandolfi@unimi.it)

30 Department of Biomedical Sciences for Health

31 University of Milan

32 Via C. Pascal 36, 20133

33 Milan, Italy

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34

35 **ABSTRACT**

36 **Background** Several municipalities in the Lombardy Region have been affected by the SARS-  
37 CoV-2 infection since the earliest stages of the epidemic. To date, 89442 confirmed cases have  
38 been diagnosed in Lombardy, and mortality in several municipalities has already surpassed that  
39 of the past decade. Currently, the true extent of the SARS-CoV-2 infection remains unknown  
40 as several affected subjects may have been asymptomatic or have presented mild disease, thus  
41 not resulting in the identified COVID-19 cases.

42 **Methods** This cross-sectional study aims to define the spread of infection within the population  
43 by determining the seroprevalence of IgG antibodies directed against SARS-CoV-2 by rapid  
44 immunochromatographic testing and subsequent confirmation by serology on venous blood by  
45 liquid phase immunochemical testing, also allowing to compare the two methods. Testing will  
46 be performed on adults and minors residing, domiciled or working in several municipalities of  
47 the Lombardy Region, involved in the initial stages of the epidemic. The study will include  
48 rapid finger-prick testing and venous sampling for antibodies against SARS-CoV-2, and  
49 nasopharyngeal swabbing (NPS). Concurrent notification of test results will occur via the  
50 regional healthcare information system (SISS).

51 **Discussion** This study was developed with the desire to understand the seroprevalence of  
52 SARS-CoV-2 infection and the epidemiological transmission characteristics of this virus.  
53 Understanding the spread and severity of the disease could help in the implementation of  
54 effective infection surveillance containment and countermeasures facilitating the identification  
55 of cases that have been exposed to the virus and the traceability of contacts.

56 **This study has been approved by the Ethics Committee of the University of Milan**  
57 **(35/2020).**

58

59 **Keywords:** SARS-CoV-2, coronavirus, COVID-19, antibodies, prevalence, rapid test,  
60 immunocromatographic test.

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

## 84 **BACKGROUND**

85

86 Several municipalities of the Lombardy Region have been affected by the Severe Acute  
87 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection since the earliest stages of the  
88 epidemic. In fact, the first so called “red zone”, a quarantined area where all movements were  
89 restricted, was established in the Lodi province (south-eastern Lombardy) on the 23<sup>rd</sup> of  
90 February, following the first Coronavirus Induced Disease (COVID-19) hospitalization from  
91 Codogno (LO).

92 To date, a total of 89442 SARS-CoV-2 cases have been confirmed in the Lombardy Region<sup>1</sup>,  
93 however the true extent of the SARS-CoV-2 infection remains unknown. In particular, the  
94 number of infected subjects having presented minimal or no symptomatology has not been  
95 precisely determined.

96 The World Health Organization (WHO) recognized the existence of a coronavirus responsible  
97 for pneumonia in Wuhan, China on December 29<sup>th</sup> 2019<sup>2</sup>. This virus, initially identified as n-  
98 CoV-2019 (novel Coronavirus 2019), was subsequently referred to as SARS-CoV-2, and its  
99 clinical manifestations known as Coronavirus Induced Disease 2019 (COVID-19). The  
100 pandemic was declared on March 11<sup>th</sup> 2020<sup>3</sup>.

101 Currently, the WHO considers forwarding scientific knowledge on mass screening essential for  
102 the battle against the spread of SARS-CoV-2, in order to allow better understanding and  
103 planning of current and future containment policies.

104 All countries that have made extensive use of diagnostic testing on the whole population,  
105 regardless of presence or absence of symptoms, have achieved a drastic drop in infection and  
106 spread<sup>4</sup>.

107 To date, the only diagnostic tool to be officially recognized by the Italian Ministry of Health  
108 for SARS-CoV-2 infection is the NPS, that uses real-time reverse transcription polymerase

109 chain reaction (rRT-PCR) to identify and amplify traces of the SARS-CoV-2 genome within a  
110 patient's samples. This diagnostic method has several limits, including high costs, long  
111 complete analysis times, and many false negatives (low diagnostic sensitivity).

112 Alongside the diagnostic aspect, the development of knowledge regarding disease spread and  
113 prevalence in the population will become increasingly important in the near future. For this  
114 reason, the development of research on seroprevalence with appropriate methods is of  
115 fundamental importance.

116 This study was developed with the desire to understand the seroprevalence of SARS-CoV-2  
117 infection and the epidemiological transmission characteristics of this virus in the earliest  
118 affected areas in Italy. Understanding the spread and severity of the disease could help in the  
119 implementation of effective infection surveillance containment and countermeasures  
120 facilitating the identification of cases that have been exposed to the virus and the traceability of  
121 contacts.

122

## 123 **METHODS & DESIGN**

124 The primary objective of this cross-sectional study is to determine the spread of infection within  
125 the population by determining the seroprevalence of IgG antibodies directed against SARS-  
126 CoV-2 by rapid immunochromatographic testing and subsequent confirmation by serology on  
127 venous blood by liquid phase immunochemical testing.

128 Secondary objectives include comparing IgG and IgM antibody positivity obtained by rapid  
129 testing via direct viral research to serological data obtained by the immunochemical method.

130 We also aim to establish a database for future prospective projects eg. serial antibody titer  
131 assessed over time, possibly expanding the study to several municipalities particularly affected  
132 by the SARS-CoV-2 epidemic around the Lombardy region. This may help localize and isolate  
133 possible current and future outbreaks.

134 For the municipalities included in first so-called “red zone”, thus more severely hit, we  
135 hypothesize a seroprevalence of IgG antibodies directed against SARS-CoV-2 between 30%  
136 and 50%, due to probable unrestricted viral circulation in the days or weeks before the first  
137 hospitalized case. For the other, less severely affected, municipalities we estimate a prevalence  
138 between 10 and 30%.

139 According to current regional legislation (DGR n. XI/3114 and DGR n. XI/3131) during the  
140 second phase of the epidemic, NPS will be performed in all symptomatic individuals, flagged  
141 as “suspect COVID-19 cases” by their family doctor, and in all traced contacts prior to  
142 readmission in society. Although rRT-PCR on NPS is the current gold standard diagnostic test  
143 for SARS-CoV-2, diagnostic accuracy depends on several pre-analytical and analytical  
144 variables, and many patients can be asymptomatic (thus currently will not receive testing in the  
145 Lombardy region). The measurement of specific COVID-19 antibodies could serve as an  
146 additional tool for disease detection and management, playing a potential key role in  
147 surveillance and screening. The latter may be even more advantageous if implemented in the  
148 form of rapid finger-prick testing. In fact, as mentioned above, one of our secondary objectives  
149 is the comparison of IgG and IgM antibody positivity obtained by rapid testing, to serological  
150 data obtained by the immunochemical method. We hypothesize that antibody detection by rapid  
151 finger-prick testing will be non-inferior to detection by venous sampling.

152 Testing will be performed at specific locations in the various municipalities, equipped with the  
153 following rooms:

- 154 • A waiting room of suitable size to allow the simultaneous presence of 8-10 evenly  
155 spaced (at least 1.8 m apart) individuals equipped with suitable PPE (surgical masks).
- 156 • A room for collection of personal data and for carrying out rapid tests.
- 157 • A room for the execution of venous blood samples.
- 158 • A room for carrying out NPS.

159       • A room for the dressing and undressing of healthcare workers.

160       • A storage room with refrigerator.

161

## 162   **Inclusion and exclusion criteria**

163   All following subjects may be included in the study:

164       1. The entire adult population living in the municipality, including residential care  
165       facilities.

166       2. All individuals over 18 who were present in the municipality on a daily basis for work  
167       reasons during the epidemic eg. law enforcement officers, traders, workers in local  
168       companies etc.

169       3. All minors residing and/or domiciled in the municipality, upon explicit  
170       parental/guardian request.

171   An absolute exclusion criterion is represented by being quarantined. However, data regarding  
172   quarantine will be taken into account for defining the dynamics of the epidemic.

173

## 174   **Population follow-up and counseling**

175       1. Individuals with **negative** results to rapid testing who do not present symptoms  
176       suggestive for acute infection will be sent home, after counseling on appropriate  
177       behaviors aimed at avoiding infection.

178       2. Individuals with **negative** results to rapid testing who, however, present symptoms  
179       suggestive for acute infection will be evaluated by medical personnel to determine the  
180       need for further investigations (imaging or ER access) and quarantined, at home or in a  
181       different location if home is deemed unsuitable, pending swab results. These individuals  
182       will receive extensive counseling on best-practices during the quarantine period.

- 183 3. Individuals with **positive** results to IgM rapid testing, regardless of IgG results, will be  
184 quarantined at home, or in a different location if home is deemed unsuitable, pending  
185 swab results. If swab results are also positive, quarantine will be confirmed and  
186 extended and counseling on best-practices during the quarantine period will be  
187 provided.
- 188 4. Individuals with **positive** results to IgG rapid testing only will be sent home, without  
189 need for fiduciary quarantine.
- 190 5. Quarantined individuals will be provided with pulse oximeter, surgical masks and  
191 extensive counseling on best-practices during the quarantine period.
- 192 6. All **swab positive** individuals, regardless of rapid test results, will be notified to local  
193 health authorities using a specific infectious disease digital notification platform for the  
194 Lombardy Region. The swab positive individual will thus be quarantined, and follow-  
195 up will be carried out by the local health authorities, as indicated in current regional  
196 protocols.

197

## 198 **Results reporting**

199 Rapid test results will be communicated in real time and a full report comprising collected  
200 anamnestic and epidemiological data, and rapid test results will be emailed or printed, according  
201 to patient preference.

202 NPS results will be communicated as follows:

- 203 - In case of a negative result, attending medical personnel will call the patient directly.
- 204 - In case of a positive result, attending medical personnel will call the patient's family  
205 doctor, who will then notify the local health authorities via the regional infectious  
206 disease digital notification platform, and communicate the positive result to the patient.

207



## 208 **Sample management**

- 209 1. Rapid tests will be analyzed by assigned staff within the timeframe suggested by the  
210 manufacturer and will then be suitably disposed of by the same staff (biohazardous  
211 waste).
- 212 2. Venous blood samples will be stored on site, refrigerated at +4°C, and transported to  
213 the lab for analysis, daily.
- 214 3. Swabs will be stored on site, refrigerated at +4°C, and transported to the lab for analysis,  
215 daily (or within 48 hours during the weekend). NPSs are placed in a triple container  
216 during transportation: the collection tube is placed in a conical tube (“falcon” type tube),  
217 and then in a spill proof box.

218

## 219 **Sampling plan and determination of sample size**

220 For the purposes of the primary objective of the study, random sampling will be carried out  
221 from the municipal registry list, stratifying by gender and conventional age classes (0-19; 20-  
222 39; 40-59; >=60). At present, geographical stratification does not seem necessary given the  
223 homogenous distribution of cases identified to date. Confirmed cases that have already been  
224 identified in the municipality must be included in the study sample with the same probability  
225 as other subjects. In fact, the rapid test and venous sample seroprevalence results on previously  
226 confirmed cases will provide further data useful for comparison.

227 A sample size of 355 subjects from a population of 4616 individuals provides a bilateral 95%  
228 confidence interval with an accuracy (half-amplitude) of 0.05 when actual prevalence is close  
229 to 0.5%. In case of higher or lower prevalence, the sample size decreases to 302 subjects in case  
230 of prevalence equaling 0.3, very close to current estimates, and to 234 subjects in case of a more  
231 skeptical prevalence hypothesis of 0.8. Considering the largest population sample combined to  
232 a possible 20% drop-out, sample size increases to 444 subjects.

233 Assuming an infinite population<sup>7,8</sup>, sample size would be determined at 402 subjects, to be  
234 increased to 503 subjects considering 20% drop-out. Thus, a sample size of around 500 subjects  
235 would seem reasonable for the main study objective.

236 Regarding the secondary objective, relating to sensitivity and specificity of the rapid test  
237 compared to the gold-standard on venous blood samples, the sample size required for a bilateral  
238 95% confidence interval with a maximum amplitude of 0.1, is 527 subjects for sensitivity and  
239 438 subjects for specificity, assuming a prevalence of 0.3 with optimal sensitivity and  
240 specificity equal to 0.9. Thus, in order for both confidence intervals to have a maximum  
241 amplitude of 0.1, the largest of the two sample sizes (527 subjects) must be chosen<sup>9</sup>. Also,  
242 sample size should be further increased to 659 subjects to allow for 20% drop-out.

243 Accordingly, in case of hypothesized sensitivity and specificity values equal to 0.8, the sample  
244 size should be increased to 880 subjects, and to 1100 subjects to include 20% drop-out.

245 However, in an optimal situation, the sample size required for the secondary objective appears  
246 compatible with that needed for the primary objective. In fact, a study that could effectively  
247 recruit at least 500 people would continue to offer expected amplitudes of confidence intervals  
248 up to 0.144 for sensitivity and <0.1 for specificity, even in conditions of lower diagnostic  
249 performance, always hypothesizing a prevalence of 0.3.

250 Sample size calculations were carried out using PASS v. 16.0.3 validated software.

251

## 252 **DISCUSSION**

### 253 **Location and testing procedures**

254 Testing will be performed at various locations in the selected municipalities, equipped with the  
255 following rooms:

- 256 • A waiting room of suitable size to allow the simultaneous presence of 8-10 evenly  
257 spaced (at least 1.8 m apart) individuals equipped with suitable PPE (surgical masks).

258 • A room for collection of personal data and performing rapid tests.

259 • A room for the execution of venous blood samples.

260 • A room for carrying out NPS.

261 • A room for the dressing and undressing of healthcare workers.

262 • A storage room with refrigerator.

263 Separate paths will be defined for the entrance and exit of tested subjects, particularly to prevent

264 loitering between individuals waiting to be tested and those already tested, as well as to prevent

265 large gatherings in confined spaces like corridors, making social distancing impracticable.

266

267 Subjects are tested as follows:

268 1. Assembly of up to 10 people every 30 minutes to be examined according to geographical

269 location. Participation in the study is voluntary. Those called upon must be equipped

270 with a correctly worn surgical mask. Security personnel will be assigned to ensure

271 correct use of PPE and compliance with safety distance.

272 2. Acquisition of informed consent.

273 3. Rapid testing for antibodies against SARS-CoV-2 in all individuals in the assembled

274 group.

275 4. Anamnestic and personal data collection on a local network electronic database and

276 printing of labels for sample identification.

277 5. Venous blood sampling in all those resulting positive to the rapid test and, at random,

278 in a proportion of negative subjects, still to be determined.

279 6. Swabbing of all individuals resulting positive to the rapid test, all people with recent

280 history of symptoms compatible with COVID-19, and in a proportion of negative

281 subjects, yet to be determined, chosen at random.

282 Given that examining the largest number of people in the shortest time possible is of paramount  
283 importance in a cross-sectional study, we decided to perform rapid testing as the first procedure,  
284 and to gather epidemiological and anamnestic data while waiting for the appropriate reading  
285 time (10 to 20 minutes). This will enable us to perform between 200 and 250 rapid tests per  
286 day.

287

### 288 **Personnel protection measures**

289 Seeing as the SARS-CoV-2 epidemic is still active in the Lombardy region, participant and  
290 personnel safety will be a main concern. Personal protective equipment (PPE) and sanitization  
291 of all rooms and equipment will be guaranteed for the all duration of the study.

292 All patients must be equipped with a correctly worn surgical mask and disposable gloves.

293 PPE will be provided according to personnel role, as follows:

- 294 1. Surgical mask and disposable gown for personnel assigned to anamnestic, personal data,  
295 and rapid test collection
- 296 2. FFP2 or equivalent filtered mask, surgical cap, visor, gloves and waterproof disposable  
297 gown for personnel assigned to NPS collection and venous sample collection.

298 Moreover, we decided to position a plexiglass barrier with a specifically-designed hole through  
299 which the rapid test is performed. This guarantees additional safety for personnel assigned to  
300 rapid testing and data collection, without the discomfort of wearing PPEs. The same barrier was  
301 proposed to the nurses assigned to venous blood sampling, but was not implemented based on  
302 previous negative experiences with this method of blood collection through the plexiglass  
303 barrier.

304 Rooms and surfaces will be sanitized three times a day using 0.1-0.5% sodium hypochlorite  
305 solution for large surfaces eg. floors, walls, chairs; and 62-71% alcohol for small surfaces  
306 (whenever there is biological contamination) and remaining instrumentation.

307 Sanitization will be carried out with disposable cloths or paper towels, to be suitably eliminated  
308 (biohazardous waste).

309 Sanitization of any medical devices (sphygmomanometer, pulse oximeter, etc.) will be carried  
310 out between each use.

311

### 312 **Data management**

313 Study data will initially be stored on a certified database of the i-Care platform, provided by  
314 MEDISPA. Subsequently, an original database will be created, in collaboration with the  
315 University of Milan Data Science Research Center, for data processing and analysis, according  
316 to i-Care database data protection requirements, from which data transfer will take place.

317 Patient data will be traceable to a completely anonymous identification code (no data from  
318 which patient identity could be derived will be recorded), thus only the doctor assigned to  
319 patient data collection and, if required, subjects authorized by national privacy regulations will  
320 be able to trace data back to the specific patient via the abovementioned identification code. In  
321 any case, these subjects are bound by confidentiality according to current legislation. Patient  
322 data will be made public only via scientific publications or conferences, and only in anonymous  
323 aggregate form, always respecting current privacy laws (including but not limited to, “*legge*  
324 *privacy*”, 18/05/2018, n. 51 Legislative Decree; and the EU (GDPR) 2016/679<sup>10</sup>).

325 The protection of individuals will also be guaranteed according to the Oviedo Convention<sup>11</sup> and  
326 the Declaration of Helsinki regarding ethical principles for medical research involving human  
327 subjects<sup>12</sup>, adopted by the World Medical Association in 1964.

328

329

330

331

332 **LIST OF ABBREVIATIONS**

333 **SARS-CoV-2** severe acute respiratory syndrome coronavirus 2

334 **COVID-19** COronaVirus Induced Disease 2019

335 **rRT-PCR** real-time reverse transcription polymerase chain reaction

336 **NPS** nasopharyngeal swab

337 **SISS** Sistema Informativo SocioSanitario (regional healthcare information system)

338 **WHO** World Health Organization

339 **PPE** personal protective equipment

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357 **BIBLIOGRAPHY**

358

359 1. Total COVID-19 cases by province. In: COVID-19 in Italy – Monitoring by the Civil  
360 Protection Department. 2020.

361 [http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce47](http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1)  
362 [8eaac82fe38d4138b1](http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1) Accessed 4 June 2020.

363 2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical  
364 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a  
365 descriptive study. *The Lancet*. 2020;395:507–13

366 3. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11  
367 March 2020. [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)  
368 [remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020) Accessed 14 Apr 2020.

369 4. WHO | Coronavirus disease (COVID-2019) R&D. WHO. World Health Organization.  
370 2020. <http://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/>  
371 Accessed 27 Mar 2020.

372 5. COVID-19 Report by ISS n. 11/2020 – Recommendations for the correct sampling,  
373 conservation and analysis of COVID-19 oro/nasopharyngeal swabs. 2020.  
374 <http://www.iss.it/documents/20126/0/Rapporto+ISS+COVID-> Accessed 14 Apr 2020.

375 6. Machin D, Campbell M, Tan SB, and Tan SH. Sample Size Tables for Clinical  
376 Studies. 3rd ed. Chichester, UK: Wiley-Blackwell; 2009.

377 7. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. 3rd ed.  
378 New York: John Wiley & Sons; 2003.

379 8. Newcombe RG. Two-Sided Confidence Intervals for the Single Proportion:  
380 Comparison of Seven Methods. In: *Statistics in Medicine*; 1998. p. 857-872.

- 381 9. Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical  
382 informatics. *Journal of Biomedical Informatics*. 2014;48:193-204.
- 383 10. Regulation (EU) 2016/679 of the European Parliament and of the council of 27 April  
384 2016 on the protection of natural persons with regard to the processing of personal  
385 data and on the free movement of such data, and repealing Directive 95/46/EC  
386 (General Data Protection Regulation) . In: EuroLex – Access to European Union law.  
387 <https://eur-lex.europa.eu/eli/reg/2016/679/oj> Accessed 7 May 2020.
- 388 11. Convention for the protection of Human Rights and Dignity of the Human Being with  
389 regard to the Application of Biology and Medicine: Convention on Human Rights and  
390 Biomedicine. In Council of Europe Treaty Office. 1997.  
391 <https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/164> Accessed on  
392 8 May 2020.
- 393 12. Declaration of Helsinki regarding ethical principles for medical research involving  
394 human subjects. In World Medical Association. [https://www.wma.net/policies-  
395 post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-  
396 human-subjects/](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/) Accessed 7 May 2020.
- 397  
398  
399  
400  
401  
402  
403  
404  
405



406 **DECLARATIONS**

407 **Ethics approval and consent to participate**

408 The study have been performed in accordance with the Declaration of Helsinki and was  
409 approved by the Ethics Committee of the University of Milan on the 21<sup>st</sup> of April 2020  
410 (reference number 35/2020). Informed consent to participate in the study will be obtained in  
411 written form from all participants, or their parent or legal guardian in case of minors.

412

413 **Consent for publication**

414 Not applicable.

415

416 **Availability of data and materials**

417 The datasets used and analysed during the current study are available from the corresponding  
418 author on reasonable request.

419

420 **Competing interests**

421 The authors declare that they have no competing interests.

422

423 **Funding**

424 This study will be carried out with the non-conditioning contribution of CISOM, Fondazione  
425 Rava, Armani C/O Unimi e Mediolanum C/O Fbf/Sacco.

426 Vittoire Scolari received support from the LabEx DEEP (ANR-11-LABX-0044, ANR-10-  
427 IDEX-0001-02)

428

429

430

431

432 **Authors' contributions**

433 MG, GP, DB, AG and FC contributed to the conception and design of the protocol and revised  
434 the manuscript;

435 EB and PB contributed to the design of the protocol, the acquisition, analysis and interpretation  
436 of data, and revision of the work;

437 RR and VS contributed to the acquisition, analysis and interpretation of data;

438 CEG and SC drafted and substantially revised the work.

439 All authors declare to approve the submitted version and agree to be personally accountable for  
440 their contributions.

441

442 **Acknowledgements**

443 The authors would like to acknowledge the substantial contribution provided by Medispa  
444 s.r.l., which contributed to the protocol by providing expertise, personnel and the informatic  
445 platform.